ClinicalTrials.gg
RecruitingNCT05171894Updated Mar 3, 2026

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT

A Phase 2 interventional study of Hemopfin+Green Light and Vehicle+Green Light in Port-wine Birthmarks, Port-Wine Stain and Nevus Flammeus, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 21 studies in Port-Wine Stain with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Port-Wine Stain · United States.

Planned enrollment
3rd of 15
84 · median 22
Started
2024
the only one that year
Phase 2
3 of 21
1 open now
Registered
19th of 21
by date
Lead sponsor
1 of 21
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Among the 21 studies in Port-Wine Stain with a site in United States, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 2, and was the 19th registered.

Port-Wine Stain

45 studies on the registry are indexed under Port-Wine Stain; 7 are open to participants now.

Browse Port-Wine Stain studies →

Open to participants now

3 of the 21 studies in Port-Wine Stain with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Port-Wine Stain studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Port-Wine Stain with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, vehicle-controlled, and sequential group Phase 2 study. Eligible subjects aged 18 to 75 years old with PWB will receive Hemoporfin PDT or vehicle PDT in 8-week cycles at fixed drug dose (5 mg/kg) and different light fluence.

Read the detailed description

This is a multi-center, randomized, double-blind, vehicle-controlled, and sequential group Phase 2 study. Eligible subjects aged 18 to 75 years old with PWB will receive Hemoporfin PDT or vehicle PDT in cycles at fixed drug dose (5 mg/kg) and different light fluences. This study will be conducted in two sequential stages, each contains the same schedule, which includes Screening Period, Treatment Period apart; subsequent treatment is based on efficacy evaluation, and End of Study.

03

Conditions studied

  • Port-wine Birthmarks
  • Port-Wine Stain
  • Nevus Flammeus

Browse trials for

Keywords

  • Hemoporfin
  • Port-wine Birthmarks
  • Port-Wine Stain
  • Nevus Flammeus
  • Photodynamic therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be 18 to 75 years of age inclusive, at the time of signing the .
  2. Subject is Fitzpatrick skin type I-VI.
  3. A male subject must agree to use during the Treatment Period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period.
  4. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    Not a woman of (WOCBP) . OR A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 30 days after the last dose of study treatment.

  5. The subject has a clinical diagnosis of PWB located i) on the extremities, trunk, caudal cervical and/or retroauricular area (Stage One); ii) on the face and/or neck (Stage Two).
  6. The longest diameter of the treatment area is ≥3 cm, and the short diameter is ≥2 cm.
  7. Subject is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  8. Subject, in the Investigator's opinion, is in good general health and free of any disease state or physical condition that may impair the evaluation of PWB or expose the subject to an unacceptable risk by study participation.
  9. If the subject has a history of epilepsy or seizure, the disease must remain stable for at least 6 months prior to C1D1.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
  2. Subject has plaque/nodular changes and severe hypertrophy within the target PWB area.
  3. Subject has Sturge-Weber syndrome.
  4. Subject has any skin pathology or condition that, in the Investigator's opinion, could interfere with the evaluation of the study drug or requires use of interfering topical, systemic, or surgical therapy.
  5. The subject has evidence of scarring within the target PWB area and/or the subject has a history of hypertrophic scarring or keloidal scarring.
  6. Subject is related to medication use and/or disease.
  7. The subject has clinical abnormalities, as determined by the Investigator, which makes them unsuitable for receiving study treatment in the Investigator's opinion at Screening.
  8. Subject has received any therapy on the treatment region that, in the Investigator's opinion, may affect the target PWB area.
  9. Subject is known or in the opinion of the Investigator likely to be noncompliant with the requirements of the study protocol (eg, due to alcoholism, drug dependency, mental incapacity).
  10. Subject has a history of either significant neurological events (such as major stroke) or a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study.
  11. Subject has an unstable cardiac disease or has any medical condition that in the opinion of the Investigator may worsen from receipt of study treatment or subject participation.
  12. The subject has a history of cutaneous photosensitization, porphyria, or photodermatosis.
  13. The subject has the need or has plans to be exposed to artificial tanning devices or excessive sunlight during the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Hemoporfin+A J/cm2 Green Light

    Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Drug: Hemopfin+Green Light

  • Experimental
    Hemoporfin+B J/cm2 Green Light

    Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Drug: Hemopfin+Green Light

  • Experimental
    Hemoporfin+C J/cm2 Green Light

    Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Drug: Hemopfin+Green Light

  • Placebo comparator
    Placebo+A J/cm2 Green Light

    Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Device: Vehicle+Green Light

  • Placebo comparator
    Placebo+B J/cm2 Green Light

    Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Device: Vehicle+Green Light

  • Placebo comparator
    Placebo+C J/cm2 Green Light

    Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Device: Vehicle+Green Light

Interventions

  • DrugHemopfin+Green Light

    All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.

    Also known as: Hemopfin photodynamic therapy

  • DeviceVehicle+Green Light

    All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.

    Also known as: saline photodynamic therapy

06

What researchers measure

Primary outcomes

  1. Stage One:Incidence of any local and systemic adverse events.

    To compare the efficacy of multiple light doses (fluence) of Hemoporfin PDT To investigate the safety of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with Port-wine birthmark (PWB) in the extremities, trunk, caudal cervical, and/or retroauricular area

    Time frame: From baseline until end of study, up to approximately 44 weeks

  2. Stage Two: Port Wine Birthmark-Investigator Global Assessment (PWB-IGA) scale score reduction.

    To compare the efficacy of multiple light doses (fluence) of Hemoporfin PDT with vehicle PDT in subjects with PWB of face and/or neck.

    Time frame: From baseline until end of study, up to approximately 44 weeks

Secondary outcomes

  1. Stage One:Change from Baseline in overall PWB-IGA severity score and other scales.

    To further evaluate the efficacy of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with PWB.

    Time frame: From baseline until end of study, up to approximately 44 weeks

  2. Stage Two: Change from Baseline in overall PWB-IGA severity score and other scales.

    To further evaluate the efficacy of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with PWB.

    Time frame: From baseline until end of study, up to approximately 44 weeks

  3. Stage Two: Incidence of any local and systemic adverse events.

    To investigate the safety of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with Port-wine birthmark (PWB)

    Time frame: From baseline until end of study, up to approximately 44 weeks

Other outcomes

  1. Stage One:Maximum observed plasma concentration (Cmax) of Hemoporfin

    To check what time will it take to reach the maximum contraction of Hemoporfin

    Time frame: On the first day of the Cycle 1 (each cycle is 56 days)

  2. Stage One:Area under the concentration-time curve (AUC 0-∞) from time 0 to infinity of Hemoporfin

    To check the drug profile for absorption, distribution, metabolism and excretion for Hemoporfin

    Time frame: On the first day of the Cycle 1 (each cycle is 56 days)

  3. Stage One:Terminal elimination half-life (t1/2) of Hemoporfin

    To check how much time Hemoporfin will take to eliminate half of it's concentration from participants.

    Time frame: On the first day of the Cycle 1 (each cycle is 56 days)

  4. Stage One:Time to Cmax (Tmax) of Hemoporfin

    To check what will be the maximum concentration participants will obtained of Hemoporfin

    Time frame: On the first day of the Cycle 1 (each cycle is 56 days)

07

Study locations

5 of 5 sites recruiting
  • UCI Health Beckman Laser Institute & Medical Clinic
    Irvine, California 92697, United States
    Recruiting
  • Dermatology Cosmetic Associates of La Jolla, Inc. d/b/a West Dermatology Research Center
    San Diego, California 92121, United States
    Recruiting
  • Miami Dermatology and Laser Institute
    Miami, Florida 33173, United States
    Recruiting
  • Maryland Dermatology, Laser, Skin & Vein Institute
    Hunt Valley, Maryland 21030, United States
    Recruiting
    • Robert A. Weiss · Contactrweiss@mdlsv.com · 410-666-3960
    • Cristi L. Myers · Contactcmyers@mdlsv.com · 410-666-2839
    • Robert A. Weiss · Principal investigator
  • St. Luke's University Health Network
    Bethlehem, Pennsylvania 18015, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Jan 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Dec 29, 2021
StartActual
Sep 21, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Apr 2027
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05171894
Responsible party
Sponsor
First posted
Dec 29, 2021
Start date
Sep 21, 2024
Primary completion
Jan 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Mar 3, 2026

Study contacts

Xuejing Cheng
Contact
xjcheng@fd-zj.com
00-86-021-58953355

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion